Zobrazeno 1 - 10
of 127
pro vyhledávání: '"Shuling, Zhou"'
Autor:
Ming Li1,2,3, Shuling Zhou1,2,3, Hong Lv1,2,3, Mengyuan Cai1,2,3, Xiaochun Wan1,2,3, Hongfen Lu1,2,3, Ruohong Shui1,2,3, Wentao Yang1,2,3 yangwt2000@163.com
Publikováno v:
Archives of Pathology & Laboratory Medicine. Apr2024, Vol. 148 Issue 4, p461-470. 10p.
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-12 (2023)
Abstract Background Breast cancer (BC) with low human epidermal growth factor receptor 2 (HER2) expression is attracting much attention due to the breakthrough progress of novel anti-HER2 antibody-drug conjugates. HER2 expression is examined in patie
Externí odkaz:
https://doaj.org/article/4ba3fc865e204921aa75583e80b003de
Autor:
Shuang Ye, Shuling Zhou, Yutuan Wu, Xuan Pei, Wei Jiang, Wanling Shi, Wentao Yang, Xiaoyan Zhou, Boer Shan, Huijuan Yang
Publikováno v:
Annals of Medicine, Vol 55, Iss 1 (2023)
AbstractIntroduction Ovarian clear cell carcinoma (OCCC) has distinct clinical and molecular features and heterogeneous prognosis. Insights into the somatic genomic abnormalities of OCCC provide the basis for deeper understanding and potential therap
Externí odkaz:
https://doaj.org/article/f0c61bfc8a0245f6a5acf40af5a4cc9a
Publikováno v:
Breast, Vol 67, Iss , Pp 1-7 (2023)
Novel anti-HER2 antibody-drug conjugates trastuzumab deruxtecan (DS-8201a) showed its effect in previously-treated HER2-low metastatic breast cancer, suggesting a promising future in HER2-low breast cancer. We retrospectively reviewed the clinicopath
Externí odkaz:
https://doaj.org/article/3106b4fc4b3a4ab7addaf132f290d2e1
Autor:
Shuling Zhou, Hong Lv, Anqi Li, Ming Li, Siyuan Zhong, Hongfen Lu, Xiaoyan Zhou, Qianming Bai, Wentao Yang
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-13 (2023)
Abstract Background Breast cancer patients of American Society of Clinical Oncology and the College of American Pathologists (ASCO/CAP) Group 2 were all HER2-negative according to the 2018 guideline, not HER2-positive as defined in the 2013 guideline
Externí odkaz:
https://doaj.org/article/9c1df24d76154bc2bc222547e27934ad
Autor:
Peng Huang, Bing Li, Mengyuan Wei, Xuchun Hao, Xi Chen, Xiaozong Huang, Wei Huang, Shuling Zhou, Xiaokang Wen, Shuguo Xie, Donglin Su
Publikováno v:
Micromachines, Vol 15, Iss 1, p 121 (2024)
Operational amplifiers (op-amps) are widely used in circuit systems. The increasing complexity of the power supply network has led to the susceptibility of the power supply port to electromagnetic interference (EMI) in circuit systems. Therefore, it
Externí odkaz:
https://doaj.org/article/687d068d4b054d3fadc180aa3a52f070
Autor:
Shuang Ye, Shuling Zhou, Siyuan Zhong, Boer Shan, Wenhua Jiang, Wentao Yang, Xu Cai, Huijuan Yang
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-7 (2022)
Abstract Background The aim of the present study was to assess the prevalence of deficient mismatch repair (MMR) in Chinese ovarian clear cell carcinoma (CCC) patients and its association with clinicopathologic features. Methods Immunohistochemistry
Externí odkaz:
https://doaj.org/article/63f27be4d5e6482eb541657e5ad5f9f6
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background This study aims to evaluate the role of the fibrinogen/albumin ratio (FAR) in predicting platinum resistance and survival outcomes of patients with ovarian clear cell carcinoma (OCCC). Methods Coagulation function and D-dimer, ser
Externí odkaz:
https://doaj.org/article/3d6069abd10c40daae8c3260bf529fca
Publikováno v:
Ecological Indicators, Vol 143, Iss , Pp 109363- (2022)
This study aims to evaluate the relationship between the agriculture economy environment, and society from the perspective of system theory and then put forward targeted suggestions for sustainable development of Anhui's agriculture in China. Based o
Externí odkaz:
https://doaj.org/article/9c031707b542491a87b4b15a77007427
Autor:
Shuheng Bai, Ling Chen, Yanli Yan, Rong Li, Yun Zhou, Xuan Wang, Haojing Kang, Zhaode Feng, Guangzu Li, Shuling Zhou, Emmanuel Kwateng Drokow, Juan Ren
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
IntroductionImmune checkpoint inhibitor (ICI) therapy has been proven to be a highly efficacious treatment for colorectal adenocarcinoma (COAD). However, it is still unclear how to identify those who might benefit the most from ICI therapy. Hypoxia f
Externí odkaz:
https://doaj.org/article/23d96a0e96b543568dafe7beca77d305